Status:
RECRUITING
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
Lead Sponsor:
University of Athens
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
45-80 years
Brief Summary
A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 mon...
Detailed Description
Disordered glucose tolerance in patients with type 2 diabetes mellitus is multifactorial and includes dysfunction not only of β-cells of the pancreas, liver and muscles, but also of the adipose tissue...
Eligibility Criteria
Inclusion
- Subject has type 2 diabetes mellitus
- Subject has high or very high cardiovascular risk
- Subject has heart failure with preserved ejection fraction
Exclusion
- Subject has type 1 diabetes mellitus
- Subject has kidney disease
- Subject has retinopathy
Key Trial Info
Start Date :
November 3 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2027
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03878706
Start Date
November 3 2017
End Date
June 30 2027
Last Update
June 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Attikon" University General Hospital
Athens, Attica, Greece, 12462